Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Kintara Therapeutics, Inc.    KTRA

KINTARA THERAPEUTICS, INC.

(KTRA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

KINTARA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)

share with twitter share with LinkedIn share with facebook
09/18/2020 | 06:29pm EDT

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

                           AND RESULTS OF OPERATIONS

This Management's Discussion and Analysis ("MD&A") contains "forward-looking
statements", within the meaning of the Private Securities Litigation Reform Act
of 1995, which represent our projections, estimates, expectations, or beliefs
concerning, among other things, financial items that relate to management's
future plans or objectives or to our future economic and financial performance.
In some cases, you can identify these statements by terminology such as "may",
"should", "plans", "believe", "will", "anticipate", "estimate", "expect"
"project", or "intend", including their opposites or similar phrases or
expressions. You should be aware that these statements are projections or
estimates as to future events and are subject to a number of factors that may
tend to influence the accuracy of the statements. These forward-looking
statements should not be regarded as a representation by us or any other person
that our events or plans will be achieved. You should not unduly rely on these
forward-looking statements, which speak only as of the date of this report.
Except as may be required under applicable securities laws, we undertake no
obligation to publicly revise any forward-looking statement to reflect
circumstances or events after the date of this report or to reflect the
occurrence of unanticipated events.

You should review the factors and risks we describe under "Risk Factors" in this
report on Form 10-K for the year ended June 30, 2020 and in our other filings
with the Securities and Exchange Commission, available at www.sec.gov. Actual
results may differ materially from any forward-looking statement.

Kintara Therapeutics, Inc. is the parent company of Del Mar (BC), a British
Columbia, Canada corporation, and Adgero Biopharmaceuticals Holdings, Inc., a
Delaware corporation ("Adgero"), which are clinical stage companies with a focus
on the development of drugs for the treatment of cancer. The Company is also the
parent company to Callco and Exchangeco which are British Columbia, Canada
corporations. Callco and Exchangeco were formed to facilitate the Reverse
Acquisition. In connection with the merger described below, the Company is also
the parent company of Adgero Biopharmaceuticals, Inc., formerly a wholly-owned
subsidiary of Adgero.

References to "we", "us", and "our", refer to Kintara Therapeutics, Inc. and our wholly-owned subsidiaries, Del Mar (BC), Adgero, Adgero Biopharmaceuticals, Inc., Callco and Exchangeco.

Corporate History


We are a Nevada corporation formed on June 24, 2009 under the name Berry Only,
Inc. On January 25, 2013, we entered into and closed an exchange agreement (the
"Exchange Agreement"), with Del Mar Pharmaceuticals (BC) Ltd. ("Del Mar (BC)"),
0959454 B.C. Ltd. ("Callco"), and 0959456 B.C. Ltd. ("Exchangeco") and the
security holders of Del Mar (BC). Upon completion of the Exchange Agreement, Del
Mar (BC) became our wholly-owned subsidiary (the "Reverse Acquisition").

On June 10, 2020, we entered into an Agreement and Plan of Merger and
Reorganization (the "Merger Agreement"), dated as of June 9, 2020, by and among
Adgero Acquisition Corp., our wholly-owned subsidiary incorporated in the State
of Delaware ("Merger Sub"), and Adgero. On August 19, 2020, upon the terms and
subject to the conditions set forth in the Merger Agreement, Merger Sub merged
with and into Adgero (the "Merger"), the separate corporate existence of Merger
Sub ceased and Adgero continued its existence under Delaware law as the
surviving corporation in the Merger and became our direct, wholly-owned
subsidiary. As a result of the Merger, each issued and outstanding share of
Adgero common stock, par value $0.0001 per share (the "Adgero Common Stock")
(other than treasury shares held by Adgero), was converted automatically into
the right to receive 1.5740 shares (the "Exchange Ratio") of our common stock,
and cash in lieu of any fractional shares. Also, each outstanding warrant to
purchase Adgero Common Stock was converted into a warrant exercisable for that
number of shares of our common stock equal to the product of (x) the aggregate
number of shares of Adgero Common Stock for which such warrant was exercisable
and (y) the Exchange Ratio.

Following the completion of the Merger, we changed our name from DelMar
Pharmaceuticals, Inc. to Kintara Therapeutics, Inc. In conjunction with the
closing of the Merger, and through a series of three private placement closings,
we issued a total of 25,028 shares of Series C Convertible Preferred Stock (the
"Series C Stock") at a purchase price of $1,000 per share for total aggregate
gross proceeds of $25 million, or net proceeds of approximately $21.7 million.

The Series C Stock was issued in three series at conversion prices equal to
$1.16, $1.214 and $1.15, respectively. As a result, we issued a total of 25,028
shares of Series C Stock, which are convertible into an aggregate 21,516,484
shares of common stock. As part of the private placement, we issued warrants to
purchase 2,504 shares of Series C Stock to the placement agent (the "Placement
Agent Warrants"). The Placement Agent Warrants have an exercise price of $1,000
per share, provide for a cashless exercise feature and are exercisable for a
period of four years from the date of the initial closing of the private
placement. The Series C Stock and the shares

                                       62

--------------------------------------------------------------------------------


of Series C Stock issuable upon exercise of the Placement Agent Warrants will be
entitled to receive dividends, payable in shares of our common stock, at a rate
of 10%, 15%, 20%, and 25%, of the number of shares of common stock issuable upon
conversion of the Series C Stock, on the 12th, 24th, 36th and 48th month
anniversary of the initial closing of the private placement, which occurred on
August 19, 2020, provided that the holder of such shares has not converted the
shares of Series C Stock prior to the applicable dividend rate.



Outstanding Securities


As of September 15, 2020, we had 23,543,892 shares of common stock issued and
outstanding, outstanding, warrants to purchase 12,446,779 shares of common
stock, warrants to purchase 2,504 Series C Preferred Stock that upon conversion
are convertible into 2,152,667 shares of common stock, outstanding stock options
to purchase 6,243,872 shares of common stock, 648,613 outstanding shares of
Series B Preferred Stock that are convertible into 162,177 shares of common
stock, 25,028 outstanding shares of Series C Preferred Stock that are
convertible into 21,516,484 shares of common stock. All warrants and stock
options are convertible, or exercisable into, one share of common stock. Each
Series B convertible preferred share is convertible into 0.25 shares of common
stock and the Series C convertible Preferred Stock (issued in three series) are
convertible into a total of 21,516,484 shares of common stock

On May 8, 2019, we effected a one-for-ten reverse stock split (the "Reverse
Stock Split") of our issued and outstanding and authorized common stock. All per
share amounts and number of shares of common stock in the MD&A and the
consolidated financial statements reflect the Reverse Stock Split. The Reverse
Stock Split does not affect the our authorized preferred stock of 5,000,000
shares; except that, pursuant to the terms of the Certificate of Designations of
Series B Convertible Preferred Stock for the issued and outstanding shares of
our Series B Convertible Preferred Stock, par value $0.001 per share (the
"Series B Preferred Stock"), the conversion price at which shares of Series B
Preferred Stock may be converted into shares of common stock will be
proportionately adjusted to reflect the Reverse Stock Split.

On June 26, 2019, we amended our articles of incorporation, as amended, to increase the number of authorized shares of common stock from 7,000,000 to 95,000,000 shares.

Related Parties


We acquired our initial patents and technology rights from Valent, an entity
owned by Dr. Dennis Brown, our Chief Scientific Officer. As a result, Valent is
a related party to us.

Selected Annual Information

The financial information reported herein has been prepared in accordance with
accounting principles generally accepted in the United States. Our functional
currency at June 30, 2020 and June 30, 2019 is the US$. The following tables
represent selected financial information for us for the periods presented.

Selected Balance Sheet data



                                             June 30,        June 30,
                                               2020            2019
                                                 $               $
               Cash and cash equivalents      2,392,402       3,718,758
               Working capital                  176,161       1,955,468
               Total assets                   2,938,137       4,037,255
               Total stockholders' equity       263,214       1,967,530




                                       63
--------------------------------------------------------------------------------

Selected Statement of Operations data

For the years ended



                                                       June 30,        June 30,
                                                         2020            2019
                                                          $                $
    Expenses
    Research and development                            3,630,024       3,662,056
    General and administrative                          4,514,520       4,736,440
    Merger costs                                        1,053,697               -
                                                        9,198,241       8,398,496
    Other (income) loss
    Change in fair value of derivative liabilities              -        

(433,503 )

    Derivative liability issue costs                            -         126,186
    Foreign exchange loss                                   2,923          17,746
    Interest income                                       (75,248 )       (60,704 )
                                                          (72,325 )      (350,275 )
    Net loss for the year                               9,125,916       8,048,221
    Series B Preferred stock dividend                       8,616          

80,431

Net loss for the year attributable to common

      stockholders                                      9,134,532       

8,128,652

    Basic and fully diluted number of shares           10,444,045       

2,574,692

    Basic and fully diluted loss per share                   0.87          
 3.16



Expenses net of non-cash, share-based compensation expense - non-GAAP


The following table discloses research and development, and general and
administrative expenses net of non-cash, share-based compensation payment
expense. The disclosure has been provided to reconcile the total operational
expenses on a GAAP basis and the non-GAAP operational expenses net of non-cash
stock-based compensation in order to provide an estimate of cash used in
research and development, and general and administrative expense. Management
uses the cash basis of expenses for forecasting and budget purposes to determine
the allocation of resources and to plan for future financing opportunities.

For the years ended



                                                           June 30,        June 30,
                                                             2020            2019
                                                               $               $
Research and development - GAAP                             3,630,024       

3,662,056

Less: non-cash share-based compensation expense              (100,231 )       (88,445 )
Research and development net of non-cash share-based,
  compensation expense- Non-GAAP                            3,529,793       

3,573,611

General and administrative - GAAP                           4,514,520       

4,736,440

Less: non-cash share-based compensation expense              (601,508 )      (901,218 )
General and administrative net of non-cash share-based,
  compensation expense - Non-GAAP                           3,913,012       3,835,222




                                       64
--------------------------------------------------------------------------------

Comparison of the years ended June 30, 2020 and June 30, 2019



                                                   Years ended
                                            June 30,        June 30,
                                              2020            2019
                                                $               $           Change $        Change %
Expenses
Research and development                     3,630,024       3,662,056         (32,032 )           (1 )
General and administrative                   4,514,520       4,736,440        (221,920 )           (5 )
Merger costs                                 1,053,697               -       1,053,697            100
                                             9,198,241       8,398,496         799,745
Other (income) loss
Change in fair value of derivative
liabilities                                          -        (433,503 )       433,503            100
Derivative liability issue costs                     -         126,186        (126,186 )         (100 )
Foreign exchange loss                            2,923          17,746         (14,823 )          (84 )
Interest income                                (75,248 )       (60,704 )       (14,544 )           24
                                               (72,325 )      (350,275 )       277,950
Net loss                                     9,125,916       8,048,221       1,077,695




Research and Development

Research and development expenses decreased slightly to $3,630,024 for the year
ended June 30, 2020 from $3,662,056 for the year ended June 30, 2019. The
decrease was largely attributable to lower preclinical research, personnel, and
intellectual property expenses partially offset by higher clinical development
costs in the current year compared to the prior year.

Preclinical research costs decreased during the year ended June 30, 2020
compared to the year ended June 30, 2019 due to the completion, or deferral, of
studies that were ongoing in the prior year as well as us focusing our resources
on our clinical studies in the current year. Personnel costs have decreased in
the year ended June 30, 2020 compared to the year ended June 30, 2019 due a
reduction in full-time employee head count in the current year compared to the
prior year. Intellectual property costs decreased in the year ended June 30,
2020 compared to the year ended June 30, 2019 as we have refined our patent
portfolio by focusing on our most important patent claims in the most strategic
jurisdictions. Patent costs can vary considerably depending on the filing of new
patents, conversion of the provisional applications to PCT applications, foreign
office actions, and actual filing costs.

Clinical development costs increased in the year ended June 30, 2020 largely due
to the initial costs we have incurred related to the GCAR GBM AGILE study. In
June 2020 we announced our acceptance of an invitation from GCAR to include
VAL-083 in GCAR's GBM AGILE study, an adaptive clinical study platform in
GBM. Upon acceptance, we incurred certain costs to initiate the preliminary
agreement. We expect our research and development costs to increase in fiscal
2021 as our GCAR GBM AGILE study commences. In addition, our planned clinical
study for REM-001 is expected to commence in the coming year.

General and Administrative


General and administrative expenses were $4,514,520 for the year ended June 30,
2020 compared to $4,736,440 for the year ended June 30, 2019. A significant
portion of the decrease was due to lower professional fees and non-cash,
share-based compensation expense partially offset by higher office and sundry
expenses in the current year compared to the prior year.

Professional fees decreased during the year ended June 30, 2020 compared to the
year ended June 30, 2019 primarily due to our proposed rights offering in the
prior year which was terminated in June 2019. As a result, the professional fees
related to the Rights Offering of $555,664 were expensed in the quarter ended
June 30, 2019.  Office and sundry has increased in the year ended June 30, 2020
compared to the year ended June 30, 2019 due primarily to costs of higher
directors' and officers' liability insurance.

In relation to general and administrative expenses during the year ended June
30, 2020, we incurred non-cash, share-based compensation expense relating to
warrants issued for services and stock option expense while during the year
ended June 30, 2019, we incurred non-cash, share-based compensation expense
relating to performance share units, warrants issued for services, and stock
option expense. All performance share units were canceled on April 30, 2019 so
there was no related expense incurred during the year ended June 30, 2020.

                                       65

--------------------------------------------------------------------------------

Merger costs

Merger costs of $1,053,697 (2019 - $Nil) relate to expenditures incurred prior to June 30, 2020 with respect to the Adgero Merger and have been expensed.

Preferred Share Dividends


For each of the years ended June 30, 2020 and 2019 we recorded $8,356 related to
the dividend payable to Valent on the Series A preferred stock. The dividend has
been recorded as a direct increase in accumulated deficit for both years.

During the year ended June 30, 2020, we issued 14,800 (2019 - 18,271) shares of
common stock as a dividend on the Series B Preferred stock and recognized $8,616
(2019 - $80,431) as a direct increase in accumulated deficit.

Liquidity and Capital Resources

Comparison of the years ended June 30, 2020 and June 30, 2019



                                             June 30,         June 30,
                                               2020             2019            Change          Change
                                                $                $                $               %

Cash flows from operating activities (7,927,516 ) (6,327,425 )

    (1,600,091 )           25

Cash flows from financing activities 6,601,160 4,074,188

    2,526,972             62




Operating Activities

Net cash used in operating activities increased to $7,927,516 for the year ended
June 30, 2020 from $6,327,425 for the year ended June 30, 2019. During the year
ended June 30, 2020 and 2019 we reported net losses of $9,125,916 and
$8,048,221, respectively. Changes in adjustments to reconcile net loss to net
cash used in operating activities for the year ended June 30, 2020 compared to
June 30, 2019 included higher warrants issued for services in the current year
due to more warrants being issued in the current year compared to the prior
year. Items incurred during the year ended June 30, 2019 but not in the year
ended June 30, 2020 include a change in the fair value of derivative liabilities
of $433,503 and performance stock unit expense of $526,141. The most significant
changes in working capital for the year ended June 30, 2020 were from uses of
cash due to an increase in non-financing related accounts payable and accrued
liabilities of $206,597, an increase in related party payables of $338,657, and
an increase in prepaid expenses of $75,332. The most significant change in
working capital for the year ended June 30, 2019 was cash from a reduction in
prepaid expenses and deposits of $754,682 largely due to a partial refund of a
clinical study deposit, and cash from an increase in accounts payable and
accrued liabilities of $202,000.

Financing Activities


During the year ended June 30, 2020, we received $6,582,966 in net proceeds from
the completion of an underwritten public offering by us of common stock,
pre-funded warrants, and common stock purchase warrants. Additionally, we
received $51,550 pursuant to the exercise of warrants in the current year. At
June 30, 2020, we have incurred $25,000 in deferred financing costs, net of
deferred financing costs included in accounts payable, related to the private
placement completed in August 2020.

During the year ended June 30, 2019, we received $3,362,379 in net proceeds from
the completion of a registered direct offering by us of common stock and common
stock purchase warrants. We also received $720,165 in net proceeds from the
exercise and exchange of warrants.

Liquidity Risk and Capital Expenditure Requirements

Liquidity Risk

(See note 1 to the consolidated financial statements)

The consolidated financial statements have been prepared on a going concern basis which assumes that we will continue our operations for the foreseeable future and contemplates the realization of assets and the settlement of liabilities in the normal course of business.

                                       66

--------------------------------------------------------------------------------


For the year ended June 30, 2020, we reported a loss of $9,125,916, and a
negative cash flow from operations of $7,927,516. We had an accumulated deficit
of $69,721,233 as of June 30, 2020. As of June 30, 2020, we had cash and cash
equivalents on hand of $2,392,402. We are in the clinical stage and have not
generated any revenues to-date. We do not have the prospect of achieving
revenues until such time that our product candidates are commercialized, or
partnered, which may not ever occur. In the future, we will require additional
funding to maintain our clinical studies, research and development projects, and
for general operations. We may tailor the development programs of our drug
candidates based on the amount of funding we are able to raise in the future.

These circumstances had indicated substantial doubt existed about our ability to
continue as a going concern. Subsequent to June 30, 2020, we completed a private
placement in three closings for gross proceeds of approximately $25 million, or
net proceeds of approximately $21.7 million. We believe that based on our
current estimates, cash on hand at June 30, 2020 and the proceeds from the
private placement, will be sufficient to fund our planned operations beyond the
next year from the date the consolidated financial statements are issued. As a
result, substantial doubt about our ability to continue as a going concern has
been alleviated. However, the COVID-19 pandemic has created significant economic
uncertainty and volatility in the credit and capital markets. The ultimate
impact of the COVID-19 pandemic on our ability to raise additional capital in
the future is unknown and will depend on future developments, which are highly
uncertain and cannot be predicted with confidence, including the duration of the
COVID-19 outbreak and any new information which may emerge concerning the
severity of the COVID-19 pandemic.

The financial statements do not give effect to any adjustments to the amounts
and classification of assets and liabilities that may be necessary should we be
unable to continue as a going concern. Such adjustments could be material.

Our future funding requirements will depend on many factors, including but not limited to:

• the rate of progress and cost of our clinical studies, preclinical studies

and other discovery and research and development activities;

• the costs associated with establishing manufacturing and commercialization

capabilities;

• the costs of acquiring or investing in businesses, product candidates and

technologies;

• the costs of filing, prosecuting, defending and enforcing any patent

claims and other intellectual property rights;

• the costs and timing of seeking and obtaining FDA and other regulatory

        approvals;


  • the effect of competing technological and market developments;

• the economic and other terms and timing of any collaboration, licensing or

        other arrangements into which we may enter; and


  • the impact of us being a public entity.


Until we can generate a sufficient amount of product revenue to finance our cash
requirements, which we may never do, we expect to finance future cash needs
primarily through public or private equity offerings, or strategic
collaborations. The sale of equity and convertible debt securities may result in
dilution to our stockholders and certain of those securities may have rights
senior to those of our shares of capital stock. If we raise additional funds
through the issuance of preferred stock, convertible debt securities or other
debt financing, these securities or other debt could contain covenants that
would restrict our operations. Any other third-party funding arrangement could
require us to relinquish valuable rights. Economic conditions may affect the
availability of funds and activity in equity markets. We do not know whether
additional funding will be available on acceptable terms, or at all. If we are
not able to secure additional funding when needed, we may have to delay, reduce
the scope of or eliminate one or more of our clinical trials or research and
development programs or make changes to our operating plan. In addition, we may
have to seek a partner for one or more of our product candidates at an earlier
stage of development, which would lower the economic value of those programs to
us.

Critical Accounting Policies

The preparation of financial statements, in conformity with generally accepted
accounting principles in the United States, requires companies to establish
accounting policies and to make estimates that affect both the amount and timing
of the recording of assets, liabilities, revenues and expenses. Some of these
estimates require judgments about matters that are inherently uncertain and
therefore actual results may differ from those estimates.

                                       67

--------------------------------------------------------------------------------


A detailed presentation of all of our significant accounting policies and the
estimates derived therefrom is included in Note 2 to our consolidated financial
statements for the year ended June 30, 2020 contained elsewhere in this report
on Form 10-K. While all of the significant accounting policies are important to
our consolidated financial statements, the following accounting policies and the
estimates derived therefrom are critical:

  • Warrants and shares issued for services


  • Stock options


  • Accruals for research and development expenses and clinical trials

Warrants and shares issued for services

We have issued equity instruments for services provided by employees and nonemployees. The equity instruments are valued at the fair value of the instrument granted.

Stock options


We recognize compensation costs resulting from the issuance of stock-based
awards to employees, non-employees and directors as an expense in the statement
of operations over the service period based on a measurement of fair value for
each stock-based award. Prior to our adoption of ASU 2018-07, Compensation-Stock
Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment
Accounting ("ASU 2018-07"), stock options granted to non-employee consultants
were revalued at the end of each reporting period until vested using the
Black-Scholes option-pricing model and the changes in their fair value were
recorded as adjustments to expense over the related vesting period. For the year
ended June 30, 2019, the determination of grant-date fair value for stock option
awards was estimated using the Black-Scholes model, which includes variables
such as the expected volatility of our share price, the anticipated exercise
behavior of its grantee, interest rates, and dividend yields. For the year ended
June 30, 2020, we utilized the plain vanilla method to determine the expected
life of stock options. These variables are projected based on our historical
data, experience, and other factors. Changes in any of these variables could
result in material adjustments to the expense recognized for share-based
payments. Such value is recognized as expense over the requisite service period,
net of actual forfeitures, using the accelerated attribution method. We
recognize forfeitures as they occur. The estimation of stock awards that will
ultimately vest requires judgment, and to the extent actual results, or updated
estimates, differ from current estimates, such amounts are recorded as a
cumulative adjustment in the period estimates are revised.

Accruals for research and development expenses and clinical trials


As part of the process of preparing our financial statements, we are required to
estimate our expenses resulting from our obligations under contracts with
vendors, clinical research organizations and consultants, and under clinical
site agreements in connection with conducting clinical trials. The financial
terms of these contracts are subject to negotiations, which vary from contract
to contract and may result in payment terms that do not match the periods over
which materials or services are provided under such contracts. Our objective is
to reflect the appropriate expenses in our financial statements by matching
those expenses with the period in which services are performed and efforts are
expended. We account for these expenses according to the timing of various
aspects of the expenses. We determine accrual estimates by taking into account
discussion with applicable personnel and outside service providers as to the
progress of clinical trials, or the services completed. During the course of a
clinical trial, we adjust our clinical expense recognition if actual results
differ from our estimates. We make estimates of our accrued expenses as of each
balance sheet date based on the facts and circumstances known to us at that
time. Our clinical trial accruals are dependent upon the timely and accurate
reporting of contract research organizations and other third-party vendors.
Although we do not expect our estimates to be materially different from amounts
actually incurred, our understanding of the status and timing of services
performed relative to the actual status and timing of services performed may
vary and may result in us reporting amounts that are too high or too low for any
particular period. For years ended June 30, 2020 and 2019, there were no
material adjustments to our prior period estimates of accrued expenses for
clinical trials.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

© Edgar Online, source Glimpses


share with twitter share with LinkedIn share with facebook
All news about KINTARA THERAPEUTICS, INC.
10/22KINTARA THERAPEUTICS : and the Global Coalition for Adaptive Research Execute Ag..
AQ
10/21KINTARA THERAPEUTICS : and the Global Coalition for Adaptive Research Execute Ag..
PR
09/22KINTARA THERAPEUTICS : Announces Fiscal Year 2020 Financial Results and Recent C..
AQ
09/21KINTARA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regu..
AQ
09/21KINTARA THERAPEUTICS : Announces Fiscal Year 2020 Financial Results and Recent C..
PR
09/18KINTARA THERAPEUTICS : Management's Discussion and Analysis of Financial Conditi..
AQ
09/01KINTARA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregis..
AQ
09/01KINTARA THERAPEUTICS : Completes Final Closing of Previously Announced Private P..
PR
08/26KINTARA THERAPEUTICS : (formerly DelMar Pharmaceuticals) to Present at the LD Mi..
PR
08/25KINTARA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregis..
AQ
More news